Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells

Gao,Jianwen; Wang,Zehua; Fu,Jiayu; A.,Jisaihan; Ohno,Yuko; Xu,Congjian

doi:10.3892/etm.2021.10367

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells

Authors:
- Jianwen Gao
- Zehua Wang
- Jiayu Fu
- Jisaihan A.
- Yuko Ohno
- Congjian Xu
View Affiliations

Affiliations: Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, Osaka 565‑0871, Japan, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, P.R. China
Published online on: July 1, 2021 https://doi.org/10.3892/etm.2021.10367
Article Number: 935
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most lethal type of gynecological cancer. Due to its high heterogeneity and complicated pathological mechanisms, the 5‑year survival rate of patients with ovarian cancer is <40%. Tumor cytoreductive surgery and systemic chemotherapy of platinum combined with paclitaxel are currently considered the gold standard for the treatment of ovarian cancer, and chemotherapy resistance has become a key constraint in improving the cure rate of ovarian cancer. Therefore, it is important to identify novel treatment methods and strategies for ovarian cancer. Targeted drugs can not only be used in combination with chemotherapy, but also act as maintenance therapy to promote patient survival time. PARP inhibitor is a novel type of ovarian cancer treatment targeted drug, which can induce an anticancer effect by inhibiting DNA damage and repair of ovarian cancer cells. The present study investigated the different effects of olaparib, cisplatin and paclitaxel in several dosages by single use and combinations on the proliferation of different human ovarian cancer cell lines, in order to verify the synergistic effects of the combinations of the three anticancer agents in pairs. The proliferation inhibitory rate of the cell lines was determined using a Cell Counting Kit‑8 assay, while the combination index (CI) value of the combination of three agents in pairs was analyzed using Compusyn software. The proliferation was observed using a crystal violet assay, and the apoptosis ratio was measured via flow cytometry. The results of the present study revealed that the combination of cisplatin with olaparib group had a higher inhibition effect than each single group and had a higher dose‑reduction index of >1 than the other two combinations at all concentrations in A2780 and OVCAR‑3 cell lines. The difference in proliferation inhibition and induced apoptosis rate of A2780 cell lines was significant in the combination of cisplatin with olaparib group and the control group (P<0.01) at 0.25x IC₅₀. For the OVCAR‑3 cell line, the difference was also significant between two groups (P<0.05). The CI values in the A2780 cell line revealed significant differences between the low‑dose group (0.0625x, 0.125x and 0.25x IC₅₀) and the high‑dose group (0.5x, 1.0x and 2.0x IC₅₀) for the group that received the combination of cisplatin with olaparib (P<0.05). The present study highlighted that the group receiving a combination of cisplatin with olaparib exhibited the most significant synergistic effects among the three combinations, particularly at low doses.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014.PubMed/NCBI View Article : Google Scholar
2	Bacalbasa N, Balescu I, Dima S, Brasoveanu V and Popescu I: Hematogenous splenic metastases as an independent negative prognosis factor at the moment of primary cytoreduction in advanced stage epithelial ovarian cancer-a single center experience. Anticancer Res. 35:5649–5654. 2015.PubMed/NCBI
3	Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 38:217–227. 2002.PubMed/NCBI View Article : Google Scholar
4	Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ and Holen I: Microvascular endothelial cell responses in vitro and in vivo: Modulation by zoledronic acid and paclitaxel? J Vasc Res. 47:481–493. 2010.PubMed/NCBI View Article : Google Scholar
5	Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A and Egger H: Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: Results and 5-year follow-up. Gynecol Oncol. 106:591–595. 2007.PubMed/NCBI View Article : Google Scholar
6	Vida A, Márton J, Mikó E and Bai P: Metabolic roles of poly(ADP-ribose) polymerases. Semin Cell Dev Bio. 65:135–143. 2017.PubMed/NCBI View Article : Google Scholar
7	Schreiber V, Dantzer F, Ame JC and de Murcia G: Poly(ADP-ribose): Novel functions for an old molecule. Nat Rev Mo Cell Bio. 7:517–528. 2006.PubMed/NCBI View Article : Google Scholar
8	Walsh CS: Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 137:343–350. 2015.PubMed/NCBI View Article : Google Scholar
9	He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, et al: Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget. 8:4156–4168. 2017.PubMed/NCBI View Article : Google Scholar
10	Phulwani NK and Kielian T: Poly (ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation. J Neurochem. 106:578–590. 2008.PubMed/NCBI View Article : Google Scholar
11	Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE and Doroshow JH: Advances in using PARP inhibitors to treat cancer. BMC Med. 10(25)2012.PubMed/NCBI View Article : Google Scholar
12	Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P and Pazdur R: Successes and challenges of PARP inhibitors in cancer therapy. Front Oncol. 5(222)2015.PubMed/NCBI View Article : Google Scholar
13	Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA and Chalmers AJ: Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther. 9:1775–1787. 2010.PubMed/NCBI View Article : Google Scholar
14	Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A and Reis-Filho JS: Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 10:1192–1199. 2011.PubMed/NCBI View Article : Google Scholar
15	Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:852–861. 2014.PubMed/NCBI View Article : Google Scholar
16	Parkes EE and Kennedy RD: Clinical application of Poly(ADP-ribose) polymerase inhibitors in high-grade serous ovarian cancer. Oncologist. 21:568–593. 2016.PubMed/NCBI View Article : Google Scholar
17	Qin C, Zhang C, Zhu F, Xu F, Chen SY, Zhang P, Li YH, Yang SY, Wei YQ, Tao L and Chen YZ: Therapeutic target database update 2014: A resource for targeted therapeutics. Nucleic Acids Res. 42 (Database Issue):D1118–D1123. 2014.PubMed/NCBI View Article : Google Scholar
18	Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, et al: Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 28:2512–2519. 2010.PubMed/NCBI View Article : Google Scholar
19	Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al: Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 106(dju089)2014.PubMed/NCBI View Article : Google Scholar
20	Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R and Gianni L: Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 111:651–659. 2014.PubMed/NCBI View Article : Google Scholar
21	Konstantinopoulos PA, Ceccaldi R, Shapiro GI and D'Andrea AD: Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5:1137–1154. 2015.PubMed/NCBI View Article : Google Scholar
22	Chou TC and Martin N: CompuSyn for Drug Combinations: PC Software and User's Guide: A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC₅₀ and ED₅₀ and LD₅₀ values. ComboSyn Inc., Paramus NJ, 2005.
23	Ashton JC: Drug combination studies and their synergy quantification using the Chou-Talalay method-letter. Cancer Res. 75(2400)2015.PubMed/NCBI View Article : Google Scholar
24	Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, et al: Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol. 16:87–97. 2015.PubMed/NCBI View Article : Google Scholar
25	Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T and Kajiyama G: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: Comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol. 12:847–854. 2001.PubMed/NCBI View Article : Google Scholar
26	Garcia A and Singh H: Bevacizumab and ovarian cancer. Ther Adv Med Oncol. 5:133–141. 2013.PubMed/NCBI View Article : Google Scholar
27	Salminen A, Ojala J and Kaarniranta K: Apoptosis and aging: Increased resistance to apoptosis enhances the aging process. Cell Mol Life Sci. 68:1021–1031. 2011.PubMed/NCBI View Article : Google Scholar
28	Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M and Kiura K: Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 11:140–148. 2013.PubMed/NCBI View Article : Google Scholar
29	Yasukawa M, Fujihara H, Fujimori H, Kawaguchi K, Yamada H, Nakayama R, Yamamoto N, Kishi Y, Hamada Y and Masutani M: Synergetic effects of PARP inhibitor AZD2281 and cisplatin in oral squamous cell carcinoma in vitro and in vivo. Int J Mol Sci. 17(272)2016.PubMed/NCBI View Article : Google Scholar
30	de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, et al: Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget. 8:60750–60763. 2017.PubMed/NCBI View Article : Google Scholar